Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $28.5 million.

  • C4 Therapeutics' Non-Current Deffered Revenue fell 30.58% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 30.58%. This contributed to the annual value of $28.5 million for FY2024, which is 30.45% up from last year.
  • Latest data reveals that C4 Therapeutics reported Non-Current Deffered Revenue of $28.5 million as of FY2024, which was up 30.45% from $21.8 million recorded in FY2023.
  • C4 Therapeutics' 5-year Non-Current Deffered Revenue high stood at $53.6 million for FY2020, and its period low was $16.9 million during FY2022.
  • Its 3-year average for Non-Current Deffered Revenue is $22.4 million, with a median of $21.8 million in 2023.
  • In the last 5 years, C4 Therapeutics' Non-Current Deffered Revenue plummeted by 54.55% in 2021 and then surged by 30.45% in 2024.
  • Over the past 5 years, C4 Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $53.6 million in 2020, then crashed by 54.55% to $24.4 million in 2021, then tumbled by 30.67% to $16.9 million in 2022, then rose by 29.12% to $21.8 million in 2023, then spiked by 30.45% to $28.5 million in 2024.